DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Pulmicort (Budesonide Inhalation) - Summary

 
 



PULMICORT SUMMARY

Budesonide, the active component of PULMICORT FLEXHALER is a corticosteroid designated chemically as (RS)-11β, 16α, 17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde.

PULMICORT FLEXHALER is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of those patients may be able to reduce or eliminate their requirement for oral corticosteroids over time.

PULMICORT FLEXHALER is NOT indicated for the relief of acute bronchospasm.


See all Pulmicort indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Pulmicort (Budesonide Inhalation)

Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. [2015]
remission in patients with ulcerative proctitis or ulcerative proctosigmoiditis... CONCLUSIONS: Budesonide rectal foam was well tolerated and more efficacious than

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. [2015]
budesonide MMX in patients with mild-to-moderate active UC... CONCLUSION: This pooled analysis showed that budesonide MMX 9 mg is efficacious,

Effects of nebulized high-dose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study. [2013]
exacerbation of asthma... CONCLUSION: On the basis of nebulized short-acting bronchodilators, addition of

Safety and Tolerability of High-Dose Budesonide/Formoterol via Turbuhaler(R) in Japanese Patients with Asthma: A Randomized, Double-Blind, Crossover, Active Comparator-Controlled, Phase III Study. [2012.01.01]
Background: The use of budesonide/formoterol as both maintenance and reliever therapy in asthma is recommended in many countries; however, there are limited data available for the Asian patient population. Objective: This study aimed to evaluate the short-term safety and tolerability of a fixed high-dose combination of the inhaled corticosteroid budesonide and the long-acting beta(2)-adrenoceptor agonist formoterol with that of the beta(2)-agonist terbutaline for acute symptom relief in Japanese adults with persistent asthma who were already receiving a combination of budesonide/formoterol maintenance therapy...

Abatacept for Crohn's disease and ulcerative colitis. [2012]
modulator, in Crohn's disease (CD) and ulcerative colitis (UC) is unknown... CONCLUSIONS: The studies showed that abatacept is not efficacious for the

more studies >>

Clinical Trials Related to Pulmicort (Budesonide Inhalation)

Adults With Moderate to Severe Asthma [Completed]
A study to compare the safety and effectiveness of 5 different ways of taking Pulmicort when given to asthma patients aged 12 years and above.

Assess the Efficacy and Safety of Rhinocort Aqua [Completed]
The purpose of this study is to compare Rhinocort with placebo in pediatric subjects aged 2-5 years with allergic rhinitis to study effects on nasal symptoms such as sneezing, runny and stuffy noses.

New Version Pulmicort Turbuhaler USA Children [Completed]
A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently approved Pulmicort Turbuhaler with a new version of the inhaler, in children and adolescents who have asthma. In addition the study evaluated the functionality of the new inhaler at the end of its intended life.

New Version Pulmicort Turbuhaler USA Adults [Completed]
A comparison of the safety, efficacy and budesonide pharmacokinetics of the currently approved Pulmicort Turbuhaler with a new version of the inhaler, in adult patients who have asthma and are currently being treated with inhaled steroids. In addition the study evaluated the functionality of the new inhaler at the end of its intended life.

Pulmicort Respules(Budesonide Inhalation Suspension) vs Singulair, Children [Completed]
A one year study comparing the safety and effectiveness of Pulmicort (0. 5mg strength given once a day in the evening) with either 4 or 5mg strength SINGULAR (given once a day in the evening) in children with asthma aged 2 to 8. If allocated to SINGULAR treatment, children aged between 2 and 5 will receive 4mg strength SINGULAR and those aged between 6 and 8 will receive 5mg strength SINGULAR.

more trials >>

Reports of Suspected Pulmicort (Budesonide Inhalation) Side Effects

Asthma (88)Dyspnoea (87)OFF Label USE (83)Drug Dose Omission (70)Malaise (62)Cough (33)Chronic Obstructive Pulmonary Disease (29)Drug Ineffective (24)Pneumonia (23)Dysphonia (18)more >>


Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015